Thymogen vs Vladonix
Comparison of Thymogen (Moderate evidence) and Vladonix (Low evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Thymogen
Dossier overview
Vladonix
Dossier overview
Overview
Thymogen and Vladonix are both studied in the peptide research space.
Thymogen: A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin.
Vladonix: A cytamin-class peptide supplement derived from thymus tissue, part of the Russian bioregulator framework.
Evidence Comparison
| Aspect | Thymogen | Vladonix |
|---|---|---|
| Evidence Level | Moderate | Low |
| Human Studies | 6 | 1 |
| Preclinical Studies | 19 | 6 |
| Total Sources | 25 | 8 |
Key Differences
| Aspect | Thymogen | Vladonix |
|---|---|---|
| Category | Immune | Immune |
| Evidence Strength | Moderate | Low |
| Total Sources | 25 | 8 |
| Human Studies | 6 | 1 |
Summary
- Thymogen: Moderate evidence with 25 total sources (6 human)
- Vladonix: Low evidence with 8 total sources (1 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.